You are entitled to your opinion In the undesrtated words of Gordon, efficacy of these drugs, i.e. Keytruda and its class of drugs, is not great and comes with significant toxicity, works well for a very small % of patients. Very evident in publications even if its worth 10 bill. On the other hand TT has very impressive efficacy, very well tolerated, and its distal effects are now coming to light, to say nothing of the wound healing post treatment. So who's piggybacking who. Not to say that qbiotics will not benefit from these partnerships. They are canny enough to explore other pathways, hence the trials in India on addition to conventional regulatory one eg. FDA. Cheers
